Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 14/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13197870 | 0.90 | MCHR1 (0.45) | MCHR1CCR2KDM4ETDP1EPHX2 | |
| SCHEMBL13197816 | 0.89 | EPHX2 (0.45) | MCHR1CCR2KDM4EEPHX2ALDH1A1 | |
| SCHEMBL13197916 | 0.89 | MCHR1 (0.48) | MCHR1CCR2TDP1EPHX2EPHX1 | |
| SCHEMBL13197911 | 0.88 | MCHR1 (0.45) | MCHR1CCR2KDM4ETDP1EPHX2 | |
| SCHEMBL2569969 | 0.87 | MCHR1 (0.44) | MCHR1CCR2KDM4EEPHX2ALDH1A1 | |
| SCHEMBL13197905 | 0.87 | MCHR1 (0.42) | MCHR1CCR2KDM4ETDP1EPHX2 | |
| SCHEMBL13197898 | 0.87 | TP53 (0.44) | MCHR1KDM4ETDP1EPHX2ALDH1A1 | |
| SCHEMBL13197887 | 0.86 | MCHR1 (0.42) | MCHR1CCR2KDM4ETDP1EPHX2 | |
| SCHEMBL13197987 | 0.85 | MCHR1 (0.44) | MCHR1KDM4EEPHX2ALDH1A1EPHX1 | |
| SCHEMBL13197879 | 0.85 | EPHX2 (0.45) | MCHR1KDM4ETDP1EPHX2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767704-B2 | Antiviral 4-aminocarbonylamino-substituted imidazole compounds | AICURIS GMBH & CO. KG (DE) | 2010-08-03 | — | — | US | disclosed |
| US-7767704-B2 | Antiviral 4-aminocarbonylamino-substituted imidazole compounds | AICURIS GMBH & CO. KG (DE) | 2010-08-03 | — | — | US | disclosed |
| US-20080004275-A1 | Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds | BAYER HEALTHCARE AG (DE) | 2008-01-03 | — | — | US | disclosed |
| US-20080004275-A1 | Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds | BAYER HEALTHCARE AG (DE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004275-A1 | Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds | IRF3, EIF2AK2, ZC3HAV1 | MCHR1 4719/4885CCR2 872/4885KDM4E 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.